https://biolegacyresearch.com/amarin-prevails-in-latest-appeal-decision-over-hikmas-generic-cardiovascular-drug/ 2024-06-26T18:35:18+00:00 https://biolegacyresearch.com/third-party-manufacturers-483-draws-2supnd-sup-crl-for-abbvies-parkinsons-candidate/ 2024-06-26T19:00:42+00:00 https://biolegacyresearch.com/quick-notes-eu-edition-june-26-2024/ 2024-06-26T19:15:02+00:00 https://biolegacyresearch.com/drugmakers-refuse-ftc-on-junk-patent-crackdown/ 2024-06-26T20:35:40+00:00 https://biolegacyresearch.com/another-crl-for-third-party-manufacturing-issues-this-time-for-merck-daiichi/ 2024-06-27T16:45:08+00:00 https://biolegacyresearch.com/research-report-june-2024/ 2024-06-27T17:35:53+00:00 https://biolegacyresearch.com/fda-changes-car-t-rems-education-adverse-event-reporting-requirements/ 2024-06-27T18:30:53+00:00 https://biolegacyresearch.com/cdrh-gates-foundation-join-forces-on-breath-based-diagnostics/ 2024-06-27T18:35:48+00:00 https://biolegacyresearch.com/philips-bipap-sees-class-i-recall-related-to-952-injuries-65-deaths/ 2024-06-28T17:15:10+00:00 https://biolegacyresearch.com/quick-notes-ma-and-collaborations-june-28-2024/ 2024-06-28T17:40:44+00:00 https://biolegacyresearch.com/regulatory-update-week-of-june-24-2024/ 2024-06-28T18:05:16+00:00 https://biolegacyresearch.com/design-of-drug-device-combo-performance-measures-is-subject-of-fda-draft-guidance/ 2024-06-28T18:50:50+00:00 https://biolegacyresearch.com/fda-approves-innovations-in-copd-drugs-in-office-hep-c-test/ 2024-06-28T19:10:53+00:00 https://biolegacyresearch.com/three-class-i-recalls-with-device-corrections-not-removals-including-a-philips-ventilator/ 2024-07-01T18:50:20+00:00 https://biolegacyresearch.com/legislative-update-week-of-july-1-2024/ 2024-07-01T19:10:51+00:00 https://biolegacyresearch.com/chmp-withholds-support-for-drugs-aimed-at-duchenne-muscular-dystrophy-als/ 2024-07-01T19:20:05+00:00 https://biolegacyresearch.com/fda-delivers-long-anticipated-guidance-on-diversity-action-plans/ 2024-07-01T19:30:01+00:00 https://biolegacyresearch.com/supremes-water-down-regulatory-agency-authority/ 2024-07-01T19:40:57+00:00 https://biolegacyresearch.com/cassava-consultant-indicted-for-fraud-sec-filing-reveals-drug-data-discrepancies/ 2024-07-02T19:14:01+00:00 https://biolegacyresearch.com/three-outcome-health-execs-sentenced-in-1b-pharma-advertising-fraud-case/ 2024-07-02T19:17:06+00:00 https://biolegacyresearch.com/cdrhs-device-advancing-tap-adds-three-device-areas-to-program/ 2024-07-02T19:19:55+00:00 https://biolegacyresearch.com/supreme-court-expands-statute-of-limitations-on-challenging-federal-rules/ 2024-07-02T19:22:02+00:00 https://biolegacyresearch.com/fda-asks-rocket-for-more-data-on-kresladi-gene-therapy/ 2024-07-03T17:00:24+00:00 https://biolegacyresearch.com/fda-approves-lillys-amyloid-targeting-alzheimers-therapy-four-other-drugs/ 2024-07-03T17:10:22+00:00 https://biolegacyresearch.com/ira-could-increase-out-of-pocket-costs-for-millions-of-part-d-seniors-report-finds/ 2024-07-03T18:00:42+00:00 https://biolegacyresearch.com/regulatory-expert-weighs-impact-of-the-ldt-final-rule/ 2024-07-03T18:30:00+00:00 https://biolegacyresearch.com/glp-1s-reduce-risk-of-10-obesity-driven-cancers-study-says/ 2024-07-05T16:35:59+00:00 https://biolegacyresearch.com/regulatory-update-week-of-july-1-2024/ 2024-07-05T16:45:56+00:00 https://biolegacyresearch.com/two-483s-note-quality-problems-at-indian-drug-api-manufacturing-plants/ 2024-07-05T17:00:26+00:00 https://biolegacyresearch.com/help-committee-letter-demands-fda-defer-to-courts-congress-on-regulations/ 2024-07-05T19:10:03+00:00 https://biolegacyresearch.com/fda-seeks-input-on-ich-draft-on-design-use-of-rwd-in-safety-assessments/ 2024-07-05T19:25:14+00:00 https://biolegacyresearch.com/fda-approves-third-alzheimers-drug-just-as-diagnostic-criteria-expand/ 2024-07-08T17:30:22+00:00 https://biolegacyresearch.com/legislative-update-week-of-july-8-2024/ 2024-07-08T17:45:33+00:00 https://biolegacyresearch.com/cber-provides-list-of-guidances-for-2024/ 2024-07-08T18:40:22+00:00 https://biolegacyresearch.com/sun-pharma-slapped-with-warning-letter-for-dadra-plants-multiple-violations/ 2024-07-08T19:00:52+00:00 https://biolegacyresearch.com/fda-publishes-draft-guidance-on-using-urras-in-combo-product-applications/ 2024-07-08T19:15:07+00:00 https://biolegacyresearch.com/class-i-recalls-for-philips-mri-coils-and-inspire-sleep-apnea-device/ 2024-07-09T17:00:57+00:00 https://biolegacyresearch.com/quick-notes-device-clearances-july-9-2024/ 2024-07-09T17:20:11+00:00 https://biolegacyresearch.com/fda-issues-draft-guidance-on-tackling-misinformation-about-approved-products/ 2024-07-09T18:00:57+00:00 https://biolegacyresearch.com/ftc-rips-pbm-consolidation-ability-to-squeeze-smaller-pharmacies-in-interim-report/ 2024-07-09T18:55:25+00:00 https://biolegacyresearch.com/ftc-supports-proposed-rule-that-would-cut-down-on-patent-system-abuse/ 2024-07-11T17:40:48+00:00 https://biolegacyresearch.com/guest-column-effects-of-the-chevron-decision-on-the-fdas-scientific-conclusions/ 2024-07-11T18:00:07+00:00 https://biolegacyresearch.com/do-not-use-certain-medtronic-emg-endotracheal-tubes-fda-warns/ 2024-07-11T18:15:11+00:00 https://biolegacyresearch.com/fda-issues-final-guidance-on-pivotal-trials-for-opioid-use-disorder-devices/ 2024-07-11T18:30:40+00:00 https://biolegacyresearch.com/novo-nordisk-gets-fda-crl-for-once-weekly-insulin-bla/ 2024-07-12T16:20:30+00:00 https://biolegacyresearch.com/fda-raises-the-bar-on-510ks-for-dental-resin-devices-ultraviolet-curing-lights/ 2024-07-12T16:48:48+00:00 https://biolegacyresearch.com/new-class-i-hamilton-ventilator-recall-updated-class-i-recalls-for-philips-megadyne/ 2024-07-12T17:00:13+00:00 https://biolegacyresearch.com/regulatory-update-week-of-july-8-2024/ 2024-07-12T17:05:25+00:00 https://biolegacyresearch.com/texas-compounder-sentenced-to-2-years-for-illegal-kickbacks-money-laundering/ 2024-07-15T17:35:43+00:00 https://biolegacyresearch.com/advamed-praises-cms-draft-rule-improving-access-to-alzheimers-cancer-diagnostics/ 2024-07-15T17:45:15+00:00 https://biolegacyresearch.com/warning-letters-for-makers-of-kids-cough-syrup-eye-drops-wound-care/ 2024-07-15T17:55:23+00:00 https://biolegacyresearch.com/legislative-update-week-of-july-15-2024/ 2024-07-15T18:05:09+00:00 https://biolegacyresearch.com/house-appropriations-committee-calls-for-halt-to-ldt-rule/ 2024-07-16T18:45:42+00:00 https://biolegacyresearch.com/baxter-now-removes-life2000-ventilator-from-use-bausch-removes-eye-injection-kit/ 2024-07-16T18:55:24+00:00 https://biolegacyresearch.com/cdrh-reorganizes-offices-to-increase-agility-meet-mdufa-commitments-priorities/ 2024-07-16T19:05:59+00:00 https://biolegacyresearch.com/quick-notes-drug-approvals-july-16-2024/ 2024-07-16T19:10:49+00:00 https://biolegacyresearch.com/final-guidance-updates-fda-combination-product-application-fees/ 2024-07-17T16:30:25+00:00 https://biolegacyresearch.com/fda-does-away-with-cbers-allergenic-products-advisory-committee/ 2024-07-17T16:40:50+00:00 https://biolegacyresearch.com/rep-jack-bergman-asks-fda-to-approve-mdma-therapy-for-veterans/ 2024-07-17T16:45:17+00:00 https://biolegacyresearch.com/fda-advises-on-pediatric-drug-development-for-inflammatory-bowel-disease-partial-onset-seizures/ 2024-07-17T16:50:24+00:00 https://biolegacyresearch.com/baxter-issues-new-ventilator-recall-philips-updates-existing-ventilator-recall/ 2024-07-18T16:15:49+00:00 https://biolegacyresearch.com/orexo-naloxone-crl-says-fda-wants-additional-study-and-more-technical-data/ 2024-07-18T16:25:32+00:00 https://biolegacyresearch.com/uk-pharma-watchdog-raps-four-drugmakers-for-breaching-industrys-code/ 2024-07-18T16:32:10+00:00 https://biolegacyresearch.com/quick-notes-eu-edition-july-18-2024/ 2024-07-18T16:35:18+00:00 https://biolegacyresearch.com/more-warning-letters-quality-issues-for-china-made-syringes/ 2024-07-19T15:40:24+00:00 https://biolegacyresearch.com/eu-experts-urge-sterile-drugmakers-to-conduct-annex-1-gap-assessment/ 2024-07-19T15:50:16+00:00 https://biolegacyresearch.com/regulatory-update-week-of-july-15-2024/ 2024-07-19T16:20:54+00:00 https://biolegacyresearch.com/fda-works-with-mark-cuban-for-import-of-short-supply-penicillin-from-portugal/ 2024-07-19T18:10:36+00:00 https://biolegacyresearch.com/rare-disease-innovation-hub-established-by-fda/ 2024-07-22T16:45:13+00:00 https://biolegacyresearch.com/chinese-drugmakers-warning-letter-cites-data-record-keeping-quality-issues/ 2024-07-22T16:52:43+00:00 https://biolegacyresearch.com/final-guidance-focuses-on-radiolabeled-mass-balance-studies-of-investigational-drugs/ 2024-07-22T16:56:11+00:00 https://biolegacyresearch.com/legislative-update-week-of-july-22-2024/ 2024-07-22T16:59:37+00:00 https://biolegacyresearch.com/regeneron-fires-back-at-dojs-charges-of-false-claim-act-violations/ 2024-07-23T15:48:09+00:00 https://biolegacyresearch.com/fda-increases-foreign-cgmp-inspections-in-2023/ 2024-07-23T15:54:48+00:00 https://biolegacyresearch.com/quick-notes-drug-approvals-july-23-2024/ 2024-07-23T16:00:25+00:00 https://biolegacyresearch.com/fda-includes-interchangeables-in-new-guidance-on-cmc-changes-for-biosimilars/ 2024-07-23T16:05:02+00:00 https://biolegacyresearch.com/house-committee-report-says-pbm-rebate-payments-stifle-generic-drugs/ 2024-07-24T15:15:26+00:00 https://biolegacyresearch.com/merck-trial-shows-infants-protected-from-rsv-by-antibody-based-vaccine/ 2024-07-24T15:25:26+00:00 https://biolegacyresearch.com/fda-seeking-info-to-develop-guidances-on-host-cell-protein-risk-and-biosimilars/ 2024-07-24T15:35:03+00:00 https://biolegacyresearch.com/fda-issues-two-final-guidances-use-of-ehrs-electronic-otc-monograph-submissions/ 2024-07-24T15:45:44+00:00 https://biolegacyresearch.com/bipartisan-house-committee-blasts-pbms-for-anticompetitive-practices/ 2024-07-25T15:20:24+00:00 https://biolegacyresearch.com/guardant-to-pay-900k-to-settle-allegations-of-violation-of-false-claims-act/ 2024-07-25T15:30:24+00:00 https://biolegacyresearch.com/quick-notes-eu-news-roundup-july-25-2024/ 2024-07-25T15:35:18+00:00 https://biolegacyresearch.com/jeff-shuren-leaving-as-director-of-cdrh-after-15-years/ 2024-07-25T15:40:18+00:00 https://biolegacyresearch.com/imfinzi-sbla-for-nonsmall-cell-lung-cancer-hits-snag-in-adcomm/ 2024-07-26T15:55:08+00:00 https://biolegacyresearch.com/doj-arrests-foreign-national-on-charges-of-selling-counterfeit-cancer-drugs/ 2024-07-26T16:00:48+00:00 https://biolegacyresearch.com/criticare-technologies-gets-warning-letter-for-patient-monitoring-system/ 2024-07-26T16:05:00+00:00 https://biolegacyresearch.com/regulatory-update-week-of-july-22-2024/ 2024-07-26T16:10:17+00:00 https://biolegacyresearch.com/ipsen-fails-again-to-get-its-tumor-drug-reclassified-as-a-biologic/ 2024-07-29T15:26:04+00:00 https://biolegacyresearch.com/fabricated-sterility-tests-earn-brassica-pharma-a-warning-letter-after-failed-inspection/ 2024-07-29T15:27:49+00:00 https://biolegacyresearch.com/quick-notes-ma-divestitures-and-collaborations-july-29-2024/ 2024-07-29T15:31:01+00:00 https://biolegacyresearch.com/legislative-update-week-of-july-29-2024/ 2024-07-29T15:38:20+00:00 https://biolegacyresearch.com/ema-panel-gives-thumbs-down-to-leqembi-for-early-alzheimers/ 2024-07-30T16:45:59+00:00 https://biolegacyresearch.com/fda-adds-digital-health-technologies-guidance-to-guidance-snapshot-pilot-program/ 2024-07-30T16:52:02+00:00 https://biolegacyresearch.com/quick-notes-device-clearances-july-30-2024/ 2024-07-30T16:58:51+00:00 https://biolegacyresearch.com/fdas-fy-2025-user-fee-schedules-notch-increases-of-up-to-44-percent/ 2024-07-30T17:38:31+00:00 https://biolegacyresearch.com/fdas-opdp-raps-kaleo-social-media-post-for-failure-to-include-risk-information/ 2024-07-31T15:35:30+00:00 https://biolegacyresearch.com/questions-and-expert-answers-on-fdas-access-rights-during-inspections/ 2024-07-31T15:45:12+00:00 https://biolegacyresearch.com/quick-notes-medical-devices-july-31-2024/ 2024-07-31T15:55:02+00:00 https://biolegacyresearch.com/amazon-walmart-other-sellers-get-warning-letters-for-unapproved-skin-peel-products/ 2024-07-31T16:00:50+00:00 https://biolegacyresearch.com/fda-slams-defibrillator-battery-maker-with-warning-letter/ 2024-08-01T16:00:59+00:00 https://biolegacyresearch.com/guest-column-what-will-the-presidential-election-bring-for-fda-policies/ 2024-08-01T16:20:37+00:00 https://biolegacyresearch.com/sponsors-can-tap-real-world-data-for-intriguing-new-ideas/ 2024-08-01T16:40:10+00:00 https://biolegacyresearch.com/novartis-sues-fda-to-prevent-marketing-of-entresto-generic/ 2024-08-01T17:40:32+00:00 https://biolegacyresearch.com/baxter-facility-draws-another-483-for-repeat-observations-of-contamination-risk/ 2024-08-02T15:20:04+00:00 https://biolegacyresearch.com/quick-notes-eu-news-roundup-aug-2-2024/ 2024-08-02T15:30:36+00:00 https://biolegacyresearch.com/regulatory-update-week-of-july-29-2024/ 2024-08-02T15:35:55+00:00 https://biolegacyresearch.com/blood-based-colorectal-cancer-screening-test-gets-thumbs-up-from-fda/ 2024-08-02T15:40:49+00:00 https://biolegacyresearch.com/new-report-addresses-trial-scarcity-mapping-trial-distribution-county-demographics/ 2024-08-05T15:35:58+00:00 https://biolegacyresearch.com/sales-of-new-drugs-exceed-development-costs-within-10-years-of-approval-study-says/ 2024-08-05T15:45:06+00:00 https://biolegacyresearch.com/legislative-update-week-of-aug-5-2024/ 2024-08-05T15:55:59+00:00 https://biolegacyresearch.com/adcomm-votes-for-arimoclomol-for-niemann-pick-disease-despite-some-data-doubts/ 2024-08-05T18:55:33+00:00 https://biolegacyresearch.com/fdas-fiscal-2025-budget-stalled-until-congress-reconvenes/ 2024-08-06T17:50:30+00:00 https://biolegacyresearch.com/new-fda-ai-tool-identifies-ae-changes-in-drug-labeling/ 2024-08-06T18:00:02+00:00 https://biolegacyresearch.com/its-time-for-fda-to-overcome-barriers-to-sharing-confidential-information-two-experts-say/ 2024-08-06T18:10:51+00:00 https://biolegacyresearch.com/quick-notes-drugs-aug-6-2024/ 2024-08-06T18:20:58+00:00 https://biolegacyresearch.com/cders-office-of-new-drugs-touts-research-outcomes-for-fiscal-2022-2023/ 2024-08-07T17:15:38+00:00 https://biolegacyresearch.com/quick-notes-drug-news-and-approvals-aug-7-2024/ 2024-08-07T17:25:21+00:00 https://biolegacyresearch.com/how-fda-handles-electronic-records-during-inspections/ 2024-08-07T17:35:42+00:00 https://biolegacyresearch.com/fda-asks-actinium-for-new-trial-on-iomab-b/ 2024-08-07T17:45:44+00:00 https://biolegacyresearch.com/bms-subsidiary-cited-for-misleading-consumers-on-lung-cancer-drugs-effectiveness/ 2024-08-08T16:28:51+00:00 https://biolegacyresearch.com/fda-invites-public-input-on-health-equity-for-medical-devices/ 2024-08-08T16:38:13+00:00 https://biolegacyresearch.com/quick-notes-ma-divestitures-and-collaborations-aug-8-2024/ 2024-08-08T16:45:28+00:00 https://biolegacyresearch.com/new-tool-offers-potential-pathway-for-adaptive-ai-devices/ 2024-08-08T16:55:16+00:00 https://biolegacyresearch.com/medtronic-smiths-medical-roll-out-fixes-for-critical-device-problems/ 2024-08-09T16:18:11+00:00 https://biolegacyresearch.com/fda-issues-final-ich-drug-interaction-studies-guidance-ich-final-bioequivalence-studies-guideline-released/ 2024-08-09T16:28:13+00:00 https://biolegacyresearch.com/cder-enhances-ai-tools-for-surveillance-in-2023/ 2024-08-09T16:38:45+00:00 https://biolegacyresearch.com/regulatory-update-week-of-aug-5-2024/ 2024-08-09T16:48:04+00:00 https://biolegacyresearch.com/cder-office-of-pharmaceutical-quality-seeks-participants-for-site-visit-program/ 2024-08-12T14:10:19+00:00 https://biolegacyresearch.com/fda-shares-case-study-of-using-ai-ml-to-identify-patients-for-covid-19-drug/ 2024-08-12T16:00:47+00:00 https://biolegacyresearch.com/lilly-touts-positive-results-from-tirzepatide-clinical-trial/ 2024-08-12T17:00:00+00:00 https://biolegacyresearch.com/legislative-update-week-of-aug-12-2024/ 2024-08-12T18:00:08+00:00 https://biolegacyresearch.com/cms-emerging-technologies-pathway-to-cover-up-to-5-new-devices-a-year/ 2024-08-13T14:18:29+00:00 https://biolegacyresearch.com/semaglutide-use-increases-more-than-400-percent-in-three-years-study-says/ 2024-08-13T15:00:00+00:00 https://biolegacyresearch.com/fda-publishes-pair-of-cancer-drug-development-guidances/ 2024-08-13T16:00:35+00:00 https://biolegacyresearch.com/quick-notes-medical-device-clearances-aug-13-2024/ 2024-08-13T17:00:11+00:00 https://biolegacyresearch.com/after-clearing-crl-ars-wins-fda-approval-of-first-nasal-spray-for-anaphylaxis/ 2024-08-14T14:24:45+00:00 https://biolegacyresearch.com/abiomed-recalls-certain-impella-devices-due-to-inspection-failures/ 2024-08-14T15:00:00+00:00 https://biolegacyresearch.com/warning-letter-walkthrough-making-monitoring-site-activation-top-priorities/ 2024-08-14T15:00:00+00:00 https://biolegacyresearch.com/why-fda-accepts-true-copies-of-records-during-inspections/ 2024-08-14T15:00:56+00:00 https://biolegacyresearch.com/bio-raps-questionable-data-in-new-studies-on-ira-impact-on-biotech-rd/ 2024-08-15T15:20:12+00:00 https://biolegacyresearch.com/fda-seeks-comments-on-eight-drugs-on-behalf-of-who/ 2024-08-15T15:23:36+00:00 https://biolegacyresearch.com/pharma-claims-devastating-consequences-from-just-released-ira-drug-pricing/ 2024-08-15T15:53:08+00:00 https://biolegacyresearch.com/novartis-loses-first-round-battle-against-generic-entresto-for-now/ 2024-08-15T17:00:14+00:00 https://biolegacyresearch.com/amgen-sues-samsung-bioepis-over-blockbuster-bone-drug-biosimilar/ 2024-08-16T14:31:58+00:00 https://biolegacyresearch.com/breas-medical-ventilators-correction-issued-for-possible-formaldehyde-exposure/ 2024-08-16T14:42:41+00:00 https://biolegacyresearch.com/idaho-combo-product-maker-gets-warning-letter-for-excess-microbial-count/ 2024-08-16T14:44:49+00:00 https://biolegacyresearch.com/regulatory-update-week-of-aug-12-2024/ 2024-08-16T15:41:00+00:00 https://biolegacyresearch.com/injectable-gel-that-stops-bullet-wound-bleeding-in-seconds-gets-clearance/ 2024-08-19T16:25:11+00:00 https://biolegacyresearch.com/us-distributor-of-tainted-eye-drops-gets-fda-warning-letter-for-failure-to-recall/ 2024-08-19T16:30:15+00:00 https://biolegacyresearch.com/quick-notes-drug-approvals-aug-19-2024/ 2024-08-19T16:35:04+00:00 https://biolegacyresearch.com/legislative-update-week-of-aug-19-2024/ 2024-08-19T16:40:03+00:00 https://biolegacyresearch.com/at-home-otc-syphilis-test-gets-fda-de-novo-marketing-nod/ 2024-08-20T15:45:18+00:00 https://biolegacyresearch.com/eli-lillys-zepbound-found-to-have-additional-clinical-benefits-in-new-study/ 2024-08-20T15:55:25+00:00 https://biolegacyresearch.com/fda-clarifies-approach-to-product-specific-guidance-meetings-for-andas/ 2024-08-20T16:05:08+00:00 https://biolegacyresearch.com/quick-notes-medical-device-clearances-and-approvals-aug-20-2024/ 2024-08-20T16:15:59+00:00 https://biolegacyresearch.com/ftc-supports-fdas-proposal-for-interchangeable-biosimilar-substitution/ 2024-08-21T16:25:10+00:00 https://biolegacyresearch.com/gao-says-challenges-remain-for-fda-monitoring-of-postmarket-devices/ 2024-08-21T16:35:31+00:00 https://biolegacyresearch.com/quick-notes-drug-news-and-approvals-aug-21-2024/ 2024-08-21T16:45:13+00:00 https://biolegacyresearch.com/what-fda-requires-in-an-electronic-document-management-system/ 2024-08-21T16:50:56+00:00 https://biolegacyresearch.com/fda-fleshes-out-policy-on-predetermined-change-control-plans-for-devices/ 2024-08-22T14:55:46+00:00 https://biolegacyresearch.com/improving-quality-management-whats-needed-to-make-actual-progress/ 2024-08-22T15:05:40+00:00 https://biolegacyresearch.com/quick-notes-drug-research-and-development-aug-22-2024/ 2024-08-22T15:15:23+00:00 https://biolegacyresearch.com/battery-life-defect-for-plum-infusion-systems-prompts-recall/ 2024-08-22T15:40:19+00:00 https://biolegacyresearch.com/fda-finalizes-guidance-on-electronic-submissions-for-de-novo-devices/ 2024-08-23T14:53:08+00:00 https://biolegacyresearch.com/lack-of-capas-mdrs-complaint-follow-up-earn-globus-a-warning-letter/ 2024-08-23T15:03:35+00:00 https://biolegacyresearch.com/quick-notes-eu-edition-aug-23-2024/ 2024-08-23T15:13:00+00:00 https://biolegacyresearch.com/regulatory-update-week-of-aug-19-2024/ 2024-08-23T15:23:27+00:00 https://biolegacyresearch.com/members-of-congress-question-fda-on-troubling-biopharma-research-in-china/ 2024-08-26T15:46:37+00:00 https://biolegacyresearch.com/do-not-use-recalled-chest-compression-device-fda-warns/ 2024-08-26T15:51:13+00:00 https://biolegacyresearch.com/quick-notes-ma-divestitures-and-collaborations-aug-26-2024/ 2024-08-26T17:00:00+00:00 https://biolegacyresearch.com/legislative-update-week-of-aug-26-2024/ 2024-08-26T18:00:00+00:00 https://biolegacyresearch.com/recall-of-inari-clot-retrieving-catheter-associated-with-six-deaths/ 2024-08-27T14:02:11+00:00 https://biolegacyresearch.com/biden-administration-awards-150m-to-8-teams-for-cancer-surgery-tech-development/ 2024-08-27T15:00:00+00:00 https://biolegacyresearch.com/quick-notes-medical-devices-aug-27-2024/ 2024-08-27T16:00:00+00:00 https://biolegacyresearch.com/pfizer-to-launch-patient-portal-for-access-to-care-prescriptions-vaccinations/ 2024-08-27T17:00:00+00:00 https://biolegacyresearch.com/fda-decision-on-regenerons-linvoseltamab-held-back-by-third-party-manufacturer/ 2024-08-28T14:55:19+00:00 https://biolegacyresearch.com/eugia-pharma-specialties-warning-letter-cites-incomplete-test-data-inaccurate-records/ 2024-08-28T15:05:03+00:00 https://biolegacyresearch.com/how-fda-judges-the-reliability-of-real-world-evidence/ 2024-08-28T15:15:43+00:00 https://biolegacyresearch.com/quick-notes-eu-edition-aug-28-2024/ 2024-08-28T15:25:17+00:00 https://biolegacyresearch.com/liveyon-ceo-pleads-guilty-to-felony-distribution-of-unapproved-stem-cell-drug/ 2024-08-29T14:35:46+00:00 https://biolegacyresearch.com/fda-firms-up-guidance-on-voluntary-malfunction-summary-reporting/ 2024-08-29T14:45:03+00:00 https://biolegacyresearch.com/sites-may-be-underprepared-for-ich-e6-revision-survey-indicates/ 2024-08-29T14:55:37+00:00 https://biolegacyresearch.com/quick-notes-drug-approvals-aug-29-2024/ 2024-08-29T15:00:04+00:00 https://biolegacyresearch.com/pharmalegacy-acquires-preclinical-cro-bts-research/ 2024-08-29T16:37:36+00:00 https://biolegacyresearch.com/wp-content/uploads/2023/05/btsresearchLogo.png https://biolegacyresearch.com/house-oversight-committee-chair-comer-asks-pbms-to-correct-hearing-testimony/ 2024-08-30T14:40:35+00:00 https://biolegacyresearch.com/carsgen-warning-letter-notes-company-paused-manufacture-following-483/ 2024-08-30T14:50:12+00:00 https://biolegacyresearch.com/quick-notes-medical-device-ma-aug-30-2024/ 2024-08-30T15:00:12+00:00 https://biolegacyresearch.com/regulatory-update-week-of-aug-26-2024/ 2024-08-30T15:10:43+00:00 https://biolegacyresearch.com/quick-notes-medical-devices-sept-5-2024/ 2024-09-05T15:05:40+00:00 https://biolegacyresearch.com/fda-guidance-calls-for-three-step-mitigation-strategy-for-nitrosamines/ 2024-09-06T16:15:19+00:00 https://biolegacyresearch.com/berkeley-biologics-draws-warning-letter-for-unapproved-bone-matrix-products/ 2024-09-06T16:25:22+00:00 https://biolegacyresearch.com/quick-notes-divestiture-and-collaboration-sept-6-2024/ 2024-09-06T16:35:24+00:00 https://biolegacyresearch.com/regulatory-update-week-of-sept-2-2024/ 2024-09-06T16:45:07+00:00 https://biolegacyresearch.com/fda-expands-guidance-on-patient-preference-information-to-include-total-product-lifecycle/ 2024-09-09T15:35:52+00:00 https://biolegacyresearch.com/eyepoint-nets-fda-warning-letter-for-eye-drug-manufacturing-issues/ 2024-09-09T15:45:36+00:00 https://biolegacyresearch.com/quick-notes-medical-devices-sept-9-2024/ 2024-09-09T15:55:40+00:00 https://biolegacyresearch.com/legislative-update-week-of-sept-9-2024/ 2024-09-09T16:05:34+00:00 https://biolegacyresearch.com/jj-on-the-hook-for-1-billion-over-breach-of-contract-fraud-in-robotics-deal/ 2024-09-10T14:42:32+00:00 https://biolegacyresearch.com/molecular-diagnostic-group-pushes-back-against-fda-regulation-filing-court-case/ 2024-09-10T14:52:10+00:00 https://biolegacyresearch.com/anumed-draws-warning-letter-for-unapproved-products-including-semaglutide/ 2024-09-10T15:00:43+00:00 https://biolegacyresearch.com/multigenerational-workforce-requires-customized-approach-to-team-building/ 2024-09-10T15:10:44+00:00 https://biolegacyresearch.com/fda-issues-letter-of-support-for-biomarker-to-detect-neurodegenerative-disorders/ 2024-09-11T15:42:42+00:00 https://biolegacyresearch.com/icer-finds-gerons-excessive-pricing-of-rytelo-may-limit-patient-access/ 2024-09-11T15:50:21+00:00 https://biolegacyresearch.com/glenmark-pays-25m-to-resolve-alleged-fca-liability-for-price-fixing-pravastatin/ 2024-09-11T16:00:52+00:00 https://biolegacyresearch.com/how-regulators-view-social-media-communications-by-drug-and-device-sponsors/ 2024-09-11T16:10:25+00:00 https://biolegacyresearch.com/ema-calls-for-safe-and-responsible-use-of-large-language-models/ 2024-09-12T14:55:07+00:00 https://biolegacyresearch.com/biocon-biologics-cited-for-ten-issues-in-form-483/ 2024-09-12T15:05:34+00:00 https://biolegacyresearch.com/quick-notes-medical-devices-sept-12-2024/ 2024-09-12T15:15:16+00:00 https://biolegacyresearch.com/small-rare-disease-trials-can-have-a-large-impact/ 2024-09-12T15:25:48+00:00 https://biolegacyresearch.com/fdanews-bids-farewell-after-50-years/ 2024-09-13T15:30:56+00:00 https://biolegacyresearch.com/fda-finalizes-guidance-on-anda-amendment-review-timeframes/ 2024-09-13T15:40:40+00:00 https://biolegacyresearch.com/dealing-with-the-big-data-challenges-facing-industry-today/ 2024-09-13T15:50:20+00:00 https://biolegacyresearch.com/regulatory-update-week-of-sept-9-2024/ 2024-09-13T16:00:55+00:00 https://biolegacyresearch.com/bts-research-successfully-completes-usda-inspection-with-zero-findings/ 2024-09-15T23:36:05+00:00 https://biolegacyresearch.com/wp-content/uploads/2023/05/btsresearchLogo.png https://biolegacyresearch.com/fda-adds-warning-about-rare-occurrence-of-serious-liver-injury-with-use-of-veozah-fezolinetant-for-hot-flashes-due-to-menopause/ 2024-09-20T18:23:09+00:00 https://biolegacyresearch.com/fda-approves-new-drug-to-treat-niemann-pick-disease-type-c/ 2024-09-24T21:30:56+00:00 https://biolegacyresearch.com/cancer-clinical-trial-eligibility-criteria-washout-periods-and-concomitant-medications-guidance-for-industry-irbs-and-clinical-investigators/ 2024-09-26T19:44:16+00:00 https://biolegacyresearch.com/fda-approves-drug-with-new-mechanism-of-action-for-treatment-of-schizophrenia/ 2024-09-26T22:40:24+00:00 https://biolegacyresearch.com/streamlining-site-feasibility-and-start-up-overcoming-challenges-and-embracing-innovation-in-clinical-research/ 2024-09-27T18:48:39+00:00 https://biolegacyresearch.com/wp-content/uploads/2024/09/WCG-2024-photo-1200-x-600-five-people-around-a-table-meeting-1024x512-1.png https://biolegacyresearch.com/coverage-analysis-for-oncology-trials-understanding-the-nuances-and-keys-to-success/ 2024-09-27T19:19:04+00:00 https://biolegacyresearch.com/fda-roundup-september-27-2024/ 2024-09-27T20:24:18+00:00 https://biolegacyresearch.com/wcgs-2024-clinical-research-site-challenges-report/ 2024-09-27T21:52:10+00:00 https://biolegacyresearch.com/complex-spinal-deformities-medical-imaging-in-clinical-trials/ 2024-09-30T14:40:00+00:00 https://biolegacyresearch.com/fdas-unified-human-foods-program-new-model-for-field-operations-and-other-modernization-efforts-go-into-effect/ 2024-10-01T13:32:08+00:00 https://biolegacyresearch.com/fda-roundup-october-1-2024/ 2024-10-01T18:40:32+00:00 https://biolegacyresearch.com/creating-a-chain-reaction-wcgs-approach-to-trust-in-clinical-trial-participation/ 2024-10-02T14:18:22+00:00 https://biolegacyresearch.com/have-a-safe-trip-clinical-and-patient-alignment-in-research-with-psychedelics/ 2024-10-02T15:51:22+00:00 https://biolegacyresearch.com/advances-in-imaging-of-rheumatoid-arthritis/ 2024-10-04T16:54:29+00:00 https://biolegacyresearch.com/fda-roundup-october-4-2024/ 2024-10-04T20:00:47+00:00 https://biolegacyresearch.com/fda-authorizes-marketing-of-first-home-flu-and-covid-19-combination-test-outside-of-emergency-use-authorities/ 2024-10-07T21:52:21+00:00 https://biolegacyresearch.com/wcg-releases-2024-report-on-top-issues-impacting-clinical-research-sites/ 2024-10-08T13:00:00+00:00 https://biolegacyresearch.com/latin-americas-continuous-cultural-exchange-and-contribution-to-clinical-research/ 2024-10-08T17:50:19+00:00 https://biolegacyresearch.com/federal-court-enters-consent-decree-against-rizo-lopez-foods-inc-following-multistate-outbreak-of-listeriosis-linked-to-queso-fresco-and-cotija-cheese-products/ 2024-10-08T20:40:05+00:00 https://biolegacyresearch.com/bts-research-earns-full-aaalac-accreditation-renewal/ 2024-10-11T16:54:15+00:00 https://biolegacyresearch.com/wp-content/uploads/2023/05/btsresearchLogo.png https://biolegacyresearch.com/tissue-iron-deposition-mri-quantitation-in-clinical-trials/ 2024-10-11T16:59:36+00:00 https://biolegacyresearch.com/fda-approves-new-treatment-for-hemophilia-a-or-b/ 2024-10-11T18:11:19+00:00 https://biolegacyresearch.com/fda-roundup-october-11-2024/ 2024-10-11T20:15:38+00:00 https://biolegacyresearch.com/the-evolving-role-of-clinical-trials-in-healthcare-insights-from-a-recent-podcast/ 2024-10-14T16:20:31+00:00 https://biolegacyresearch.com/fda-roundup-october-15-2024/ 2024-10-15T17:21:10+00:00 https://biolegacyresearch.com/maximizing-the-power-of-central-irbs-prior-to-the-fdas-sirb-mandate/ 2024-10-16T19:39:09+00:00 https://biolegacyresearch.com/neurological-imaging-contrast-enhancement-in-clinical-trials/ 2024-10-18T13:00:00+00:00 https://biolegacyresearch.com/fda-roundup-october-18-2024/ 2024-10-18T20:15:57+00:00 https://biolegacyresearch.com/the-human-side-of-clinical-trials-patients-progress-and-participation/ 2024-10-21T15:18:39+00:00 https://biolegacyresearch.com/76-million-in-illegal-e-cigarettes-seized-in-joint-federal-operation/ 2024-10-22T14:31:17+00:00 https://biolegacyresearch.com/fda-roundup-october-25-2024/ 2024-10-25T18:46:37+00:00 https://biolegacyresearch.com/fda-roundup-october-29-2024/ 2024-10-29T19:29:52+00:00 https://biolegacyresearch.com/fda-roundup-november-1-2024/ 2024-11-01T19:16:54+00:00 https://biolegacyresearch.com/fda-roundup-november-5-2024/ 2024-11-05T22:29:13+00:00 https://biolegacyresearch.com/fda-proposes-ending-use-of-oral-phenylephrine-as-otc-monograph-nasal-decongestant-active-ingredient-after-extensive-review/ 2024-11-07T14:26:17+00:00 https://biolegacyresearch.com/fda-roundup-november-8-2024/ 2024-11-08T20:05:54+00:00 https://biolegacyresearch.com/fda-approves-first-gene-therapy-for-treatment-of-aromatic-l-amino-acid-decarboxylase-deficiency/ 2024-11-14T13:49:40+00:00 https://biolegacyresearch.com/fda-roundup-november-15-2024/ 2024-11-15T20:25:24+00:00 https://biolegacyresearch.com/fda-roundup-november-19-2024/ 2024-11-19T20:39:18+00:00 https://biolegacyresearch.com/fda-roundup-november-22-2024/ 2024-11-22T19:49:14+00:00 https://biolegacyresearch.com/fda-roundup-november-26-2024/ 2024-11-26T19:40:42+00:00 https://biolegacyresearch.com/usda-fda-seek-information-about-food-date-labeling-aim-is-to-provide-further-clarity-transparency-and-cost-savings-for-u-s-consumers/ 2024-12-03T18:08:15+00:00 https://biolegacyresearch.com/fda-roundup-december-3-2024/ 2024-12-03T20:52:13+00:00 https://biolegacyresearch.com/fda-roundup-december-6-2024/ 2024-12-06T20:08:29+00:00 https://biolegacyresearch.com/fda-roundup-december-10-2024/ 2024-12-10T19:56:23+00:00 https://biolegacyresearch.com/fda-roundup-december-13-2024/ 2024-12-13T19:33:24+00:00 https://biolegacyresearch.com/fda-approves-new-treatment-for-congenital-adrenal-hyperplasia/ 2024-12-13T22:53:08+00:00 https://biolegacyresearch.com/fda-roundup-december-17-2024/ 2024-12-17T21:20:09+00:00 https://biolegacyresearch.com/fda-approves-first-mesenchymal-stromal-cell-therapy-to-treat-steroid-refractory-acute-graft-versus-host-disease/ 2024-12-18T21:40:14+00:00 https://biolegacyresearch.com/fda-updates-healthy-claim-providing-a-refreshed-tool-for-consumers/ 2024-12-19T16:39:17+00:00 https://biolegacyresearch.com/fda-approves-first-acellular-tissue-engineered-vessel-to-treat-vascular-trauma-in-extremities/ 2024-12-20T14:25:00+00:00 https://biolegacyresearch.com/fda-roundup-december-20-2024/ 2024-12-20T19:28:04+00:00 https://biolegacyresearch.com/fda-approves-first-medication-for-obstructive-sleep-apnea/ 2024-12-20T22:03:40+00:00 https://biolegacyresearch.com/fda-approves-first-generic-of-once-daily-glp-1-injection-to-lower-blood-sugar-in-patients-with-type-2-diabetes/ 2024-12-23T16:24:49+00:00 https://biolegacyresearch.com/fda-proposes-rule-to-require-standardized-testing-methods-for-detecting-and-identifying-asbestos-in-talc-containing-cosmetic-products/ 2024-12-26T17:08:07+00:00 https://biolegacyresearch.com/fda-roundup-december-27-2024/ 2024-12-27T20:22:23+00:00 https://biolegacyresearch.com/serious-liver-injury-being-observed-in-patients-without-cirrhosis-taking-ocaliva-obeticholic-acid-to-treat-primary-biliary-cholangitis/ 2025-01-02T14:44:37+00:00 https://biolegacyresearch.com/fda-roundup-january-3-2025/ 2025-01-03T19:19:21+00:00 https://biolegacyresearch.com/fda-proposes-updated-recommendations-to-help-improve-performance-of-pulse-oximeters-across-skin-tones/ 2025-01-06T14:04:08+00:00 https://biolegacyresearch.com/fda-issues-comprehensive-draft-guidance-for-developers-of-artificial-intelligence-enabled-medical-devices/ 2025-01-06T15:16:00+00:00 https://biolegacyresearch.com/fda-proposes-framework-to-advance-credibility-of-ai-models-used-for-drug-and-biological-product-submissions/ 2025-01-06T15:28:18+00:00 https://biolegacyresearch.com/fda-issues-draft-guidance-on-including-tissue-biopsies-in-clinical-trials/ 2025-01-06T16:38:10+00:00 https://biolegacyresearch.com/fda-roundup-january-7-2025/ 2025-01-07T21:31:18+00:00 https://biolegacyresearch.com/fda-roundup-january-10-2025/ 2025-01-10T20:03:25+00:00 https://biolegacyresearch.com/fda-proposes-requiring-at-a-glance-nutrition-information-on-the-front-of-packaged-foods/ 2025-01-14T14:33:54+00:00 https://biolegacyresearch.com/fda-roundup-january-14-2025/ 2025-01-14T20:40:18+00:00 https://biolegacyresearch.com/fda-proposes-significant-step-toward-reducing-nicotine-to-minimally-or-nonaddictive-level-in-cigarettes-and-certain-other-combusted-tobacco-products/ 2025-01-15T14:08:02+00:00 https://biolegacyresearch.com/fda-authorizes-marketing-of-20-zyn-nicotine-pouch-products-after-extensive-scientific-review/ 2025-01-16T16:05:42+00:00 https://biolegacyresearch.com/fda-roundup-january-17-2025/ 2025-01-17T21:03:10+00:00 https://biolegacyresearch.com/fda-approves-novel-non-opioid-treatment-for-moderate-to-severe-acute-pain/ 2025-01-30T22:44:19+00:00 https://biolegacyresearch.com/fda-alerts-patients-of-potential-to-miss-critical-safety-alerts-due-to-phone-settings-when-using-smartphone-compatible-diabetes-devices/ 2025-02-05T16:35:14+00:00 https://biolegacyresearch.com/fda-approves-first-rapid-acting-insulin-biosimilar-product-for-treatment-of-diabetes/ 2025-02-14T19:59:34+00:00 https://biolegacyresearch.com/fda-approves-first-treatment-for-cerebrotendinous-xanthomatosis-a-rare-lipid-storage-disease/ 2025-02-21T16:47:20+00:00 https://biolegacyresearch.com/bts-research-expansion-in-vitro-labs-new-san-diego-facility/ 2025-02-24T19:45:25+00:00 https://biolegacyresearch.com/wp-content/uploads/2023/05/btsresearchLogo.png https://biolegacyresearch.com/fda-roundup-february-28-2025/ 2025-02-28T20:44:55+00:00 https://biolegacyresearch.com/fda-roundup-march-4-2025/ 2025-03-04T21:31:17+00:00 https://biolegacyresearch.com/fda-roundup-march-7-2025/ 2025-03-07T20:53:15+00:00 https://biolegacyresearch.com/fda-roundup-march-11-2025/ 2025-03-11T19:24:55+00:00 https://biolegacyresearch.com/fda-educational-efforts-prevented-nearly-450000-youth-from-starting-e-cigarette-use-in-one-year/ 2025-03-14T14:11:34+00:00 https://biolegacyresearch.com/fda-roundup-march-14-2025/ 2025-03-14T19:17:51+00:00 https://biolegacyresearch.com/hhs-fda-announce-operation-stork-speed-to-expand-options-for-safe-reliable-and-nutritious-infant-formula-for-american-families/ 2025-03-18T18:20:23+00:00 https://biolegacyresearch.com/fda-roundup-march-18-2025/ 2025-03-18T19:06:49+00:00 https://biolegacyresearch.com/hhs-fda-announce-chemical-contaminants-transparency-tool-for-foods/ 2025-03-20T18:06:37+00:00 https://biolegacyresearch.com/fda-roundup-march-21-2025/ 2025-03-21T19:44:32+00:00 https://biolegacyresearch.com/fda-grants-marketing-authorization-of-first-home-test-for-chlamydia-gonorrhea-and-trichomoniasis/ 2025-03-28T13:30:19+00:00 https://biolegacyresearch.com/fda-roundup-march-28-2025/ 2025-03-28T17:48:52+00:00 https://biolegacyresearch.com/fda-approves-novel-treatment-for-hemophilia-a-or-b-with-or-without-factor-inhibitors/ 2025-03-28T18:17:40+00:00 https://biolegacyresearch.com/martin-a-makary-m-d-m-p-h-sworn-in-as-fda-commissioner/ 2025-04-01T16:45:41+00:00 https://biolegacyresearch.com/fda-announces-plan-to-phase-out-animal-testing-requirement-for-monoclonal-antibodies-and-other-drugs/ 2025-04-10T19:33:07+00:00 https://biolegacyresearch.com/fda-honored-to-welcome-hhs-secretary-robert-f-kennedy-jr-to-fda-campus/ 2025-04-11T21:01:19+00:00 https://biolegacyresearch.com/fda-commissioner-makary-announces-new-policy-on-individuals-serving-on-fda-advisory-committees/ 2025-04-17T18:59:30+00:00 https://biolegacyresearch.com/hhs-fda-to-phase-out-petroleum-based-synthetic-dyes-in-nations-food-supply/ 2025-04-22T20:12:17+00:00 https://biolegacyresearch.com/fda-announces-expanded-use-of-unannounced-inspections-at-foreign-manufacturing-facilities/ 2025-05-06T15:10:54+00:00 https://biolegacyresearch.com/fda-announces-completion-of-first-ai-assisted-scientific-review-pilot-and-aggressive-agency-wide-ai-rollout-timeline/ 2025-05-08T14:57:05+00:00 https://biolegacyresearch.com/fda-approves-three-food-colors-from-natural-sources/ 2025-05-09T14:37:51+00:00 https://biolegacyresearch.com/fda-and-nih-announce-innovative-joint-nutrition-regulatory-science-program/ 2025-05-09T16:36:43+00:00 https://biolegacyresearch.com/hhs-fda-issue-rfi-on-deregulatory-plan-to-lower-costs-and-empower-providers/ 2025-05-13T13:27:14+00:00 https://biolegacyresearch.com/hhs-fda-initiate-comprehensive-review-of-nutrients-in-infant-formula/ 2025-05-13T13:50:51+00:00 https://biolegacyresearch.com/fda-begins-action-to-remove-ingestible-fluoride-prescription-drug-products-for-children-from-the-market/ 2025-05-13T15:03:46+00:00 https://biolegacyresearch.com/fda-advances-robust-transparent-post-market-chemical-review-program-to-keep-food-supply-safe-and-healthy/ 2025-05-15T21:19:08+00:00 https://biolegacyresearch.com/fda-to-host-inaugural-independent-scientific-expert-panel-open-to-public/ 2025-05-16T16:48:13+00:00 https://biolegacyresearch.com/fda-clears-first-blood-test-used-in-diagnosing-alzheimers-disease/ 2025-05-16T17:26:43+00:00 https://biolegacyresearch.com/fda-takes-steps-to-enhance-state-importation-programs-to-help-lower-prescription-drug-prices/ 2025-05-21T13:06:03+00:00 https://biolegacyresearch.com/fda-and-cbp-seize-nearly-34-million-worth-of-illegal-e-cigarettes-during-joint-operation/ 2025-05-22T13:02:42+00:00 https://biolegacyresearch.com/fda-takes-action-to-address-data-integrity-concerns-with-two-chinese-third-party-testing-firms/ 2025-05-22T17:23:22+00:00 https://biolegacyresearch.com/fda-launches-agency-wide-ai-tool-to-optimize-performance-for-the-american-people/ 2025-06-02T19:15:18+00:00 https://biolegacyresearch.com/fda-to-issue-new-commissioners-national-priority-vouchers-to-companies-supporting-u-s-national-interests/ 2025-06-17T14:46:48+00:00 https://biolegacyresearch.com/fda-halts-new-clinical-trials-that-export-americans-cells-to-foreign-labs-in-hostile-countries-for-genetic-engineering/ 2025-06-18T22:00:56+00:00 https://biolegacyresearch.com/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-for-autologous-chimeric-antigen-receptor-car-t-cell-immunotherapies/ 2025-06-27T20:16:44+00:00 https://biolegacyresearch.com/fda-encourages-industry-leaders-to-streamline-enhance-product-recall-communications-to-safeguard-foods-for-infants-and-children/ 2025-07-09T19:45:27+00:00 https://biolegacyresearch.com/fda-embraces-radical-transparency-by-publishing-complete-response-letters/ 2025-07-10T12:17:46+00:00 https://biolegacyresearch.com/a-statement-from-fda-commissioner-marty-makary-m-d-m-p-h-100-days-of-embracing-gold-standard-science-transparency-and-common-sense/ 2025-07-10T15:03:31+00:00 https://biolegacyresearch.com/fda-approves-gardenia-genipin-blue-color-additive-while-encouraging-faster-phase-out-of-fdc-red-no-3/ 2025-07-14T12:59:50+00:00 https://biolegacyresearch.com/fda-issues-warning-letters-to-firms-marketing-products-containing-7-hydroxymitragynine/ 2025-07-15T14:01:54+00:00 https://biolegacyresearch.com/fda-to-revoke-52-obsolete-standards-of-identity-for-food-products/ 2025-07-16T15:23:02+00:00 https://biolegacyresearch.com/fda-requests-sarepta-therapeutics-suspend-distribution-of-elevidys-and-places-clinical-trials-on-hold-for-multiple-gene-therapy-products-following-3-deaths/ 2025-07-18T22:49:56+00:00 https://biolegacyresearch.com/stanford-faculty-member-george-tidmarsh-m-d-ph-d-named-director-of-center-for-drug-evaluation-and-research/ 2025-07-21T10:57:14+00:00 https://biolegacyresearch.com/official-company-name-change-announcement/ 2025-07-21T19:46:13+00:00 https://biolegacyresearch.com/wp-content/uploads/2025/07/btsresearchCTABGjuly2025c.jpg https://biolegacyresearch.com/hhs-fda-praise-consumer-brands-associations-vow-to-remove-artificial-colors-from-americas-food-supply/ 2025-07-22T18:17:07+00:00 https://biolegacyresearch.com/hhs-fda-and-usda-address-the-health-risks-of-ultra-processed-foods/ 2025-07-23T21:44:12+00:00 https://biolegacyresearch.com/fda-investigating-death-of-8-year-old-boy-who-received-elevidys/ 2025-07-25T21:25:06+00:00 https://biolegacyresearch.com/fda-recommends-removal-of-voluntary-hold-for-elevidys-for-ambulatory-patients/ 2025-07-28T20:21:55+00:00 https://biolegacyresearch.com/fda-takes-steps-to-restrict-7-oh-opioid-products-threatening-american-consumers/ 2025-07-29T14:41:37+00:00 https://biolegacyresearch.com/fda-requires-major-changes-to-opioid-pain-medication-labeling-to-emphasize-risks/ 2025-07-31T19:24:28+00:00 https://biolegacyresearch.com/fda-names-top-hhs-lawyer-as-chief-counsel/ 2025-08-04T19:42:12+00:00 https://biolegacyresearch.com/fda-announces-new-fda-precheck-program-to-boost-u-s-drug-manufacturing/ 2025-08-07T13:32:05+00:00 https://biolegacyresearch.com/a-statement-from-fda-commissioner-marty-makary-m-d-m-p-h-announcing-resolution-of-the-iv-saline-solutions-shortage/ 2025-08-08T15:25:35+00:00 https://biolegacyresearch.com/fda-commissioner-makary-usda-secretary-rollins-celebrate-proposed-modernization-of-orange-juice-regulations-to-benefit-american-growers/ 2025-08-08T19:30:37+00:00 https://biolegacyresearch.com/statement-from-fda-commissioner-marty-makary-m-d-m-p-h-on-florida-restriction-of-7-oh-opioid-products/ 2025-08-13T18:43:49+00:00 https://biolegacyresearch.com/fda-approves-first-immunotherapy-for-recurrent-respiratory-papillomatosis/ 2025-08-14T22:11:48+00:00 https://biolegacyresearch.com/hhs-allows-fda-emergency-use-of-animal-drugs-to-combat-new-world-screwworm-protect-u-s-food-supply/ 2025-08-19T12:45:21+00:00 https://biolegacyresearch.com/fda-begins-real-time-reporting-of-adverse-event-data/ 2025-08-22T15:46:16+00:00 https://biolegacyresearch.com/fda-urges-nicotine-pouch-manufacturers-to-use-child-resistant-packaging-following-increasing-reports-of-accidental-exposure/ 2025-09-02T14:59:10+00:00 https://biolegacyresearch.com/fda-advances-rare-disease-drug-development-with-new-evidence-principles/ 2025-09-03T17:59:25+00:00 https://biolegacyresearch.com/fda-announces-real-time-release-of-complete-response-letters-posts-previously-unpublished-batch-of-89/ 2025-09-04T13:23:32+00:00 https://biolegacyresearch.com/fda-launches-green-list-to-protect-americans-from-illegal-imported-glp-1-drug-ingredients/ 2025-09-05T15:05:29+00:00 https://biolegacyresearch.com/fda-approves-expanded-use-of-vonvendi-for-von-willebrand-disease-including-for-certain-uses-for-children/ 2025-09-05T21:34:10+00:00 https://biolegacyresearch.com/fda-launches-crackdown-on-deceptive-drug-advertising/ 2025-09-09T22:41:53+00:00 https://biolegacyresearch.com/fda-issues-new-guidance-to-expand-non-opioid-options-for-chronic-pain-curb-misuse/ 2025-09-10T13:04:28+00:00 https://biolegacyresearch.com/hhs-cbp-seize-86-5-million-worth-of-illegal-e-cigarettes-in-largest-ever-operation/ 2025-09-10T19:01:10+00:00 https://biolegacyresearch.com/fda-launches-real-time-adverse-event-reporting-dashboard-for-cosmetic-products/ 2025-09-12T20:08:07+00:00 https://biolegacyresearch.com/fda-grants-accelerated-approval-to-first-treatment-for-barth-syndrome/ 2025-09-19T20:47:27+00:00 https://biolegacyresearch.com/fda-takes-action-to-make-a-treatment-available-for-autism-symptoms/ 2025-09-22T21:16:16+00:00 https://biolegacyresearch.com/fda-responds-to-evidence-of-possible-association-between-autism-and-acetaminophen-use-during-pregnancy/ 2025-09-22T21:16:46+00:00 https://biolegacyresearch.com/biolegacy-research-passes-usda-inspection-with-zero-findings/ 2025-09-24T20:09:05+00:00 https://biolegacyresearch.com/wp-content/uploads/2025/09/btsresearchCTABGsept2025.jpg https://biolegacyresearch.com/fda-removes-risk-evaluation-and-mitigation-strategies-rems-for-caprelsa-vandetanib/ 2025-09-25T17:57:44+00:00 https://biolegacyresearch.com/fda-authorizes-marketing-of-first-eyeglass-lenses-to-slow-progression-of-pediatric-myopia/ 2025-09-25T18:01:03+00:00 https://biolegacyresearch.com/a-statement-from-fda-commissioner-marty-makary-m-d-m-p-h-encouraging-retailers-to-stop-selling-illegal-vapes/ 2025-09-30T13:00:57+00:00 https://biolegacyresearch.com/fda-conditionally-approves-first-drug-for-prevention-and-treatment-of-new-world-screwworm-infestations-in-cattle/ 2025-09-30T18:09:53+00:00 https://biolegacyresearch.com/fda-awards-first-ever-national-priority-vouchers-to-nine-sponsors/ 2025-10-16T20:57:23+00:00 https://biolegacyresearch.com/fda-publishes-filing-checklists-to-prevent-submission-delays/ 2025-10-23T14:35:49+00:00 https://biolegacyresearch.com/fda-issues-emergency-use-authorization-for-new-world-screwworm-drug-for-dogs/ 2025-10-24T20:31:41+00:00 https://biolegacyresearch.com/fda-moves-to-accelerate-biosimilar-development-and-lower-drug-costs/ 2025-10-29T17:01:50+00:00 https://biolegacyresearch.com/fda-acts-to-protect-children-from-unapproved-fluoride-drug-products/ 2025-10-31T17:01:52+00:00 https://biolegacyresearch.com/fda-warns-companies-over-illegal-marketing-of-botox-and-related-products/ 2025-11-05T18:44:39+00:00 https://biolegacyresearch.com/fda-awards-second-batch-of-national-priority-vouchers/ 2025-11-06T18:49:01+00:00 https://biolegacyresearch.com/hhs-advances-womens-health-removes-misleading-fda-warnings-on-hormone-replacement-therapy/ 2025-11-10T17:30:07+00:00 https://biolegacyresearch.com/longtime-fda-innovator-appointed-as-director-of-center-for-drug-evaluation-and-research/ 2025-11-11T21:19:53+00:00 https://biolegacyresearch.com/fda-approves-new-safety-warning-and-revised-indication-that-limits-use-for-elevidys-following-reports-of-fatal-liver-injury/ 2025-11-14T18:44:08+00:00 https://biolegacyresearch.com/fda-pilots-faster-clarifications-to-meeting-minutes/ 2025-11-19T21:04:49+00:00 https://biolegacyresearch.com/fda-approves-gene-therapy-for-treatment-of-spinal-muscular-atrophy/ 2025-11-24T22:24:36+00:00 https://biolegacyresearch.com/bts-research-completes-corrections-of-fda-483-observations/ 2025-11-26T14:09:30+00:00 https://biolegacyresearch.com/wp-content/uploads/2024/02/July2025_BiolegacyFinal_v7_Icon_Color-1.png https://biolegacyresearch.com/wp-content/uploads/2023/05/btsresearchLogo.png https://biolegacyresearch.com/biolegacy-research-successfully-passes-2025-fda-inspection/ 2025-12-21T23:21:10+00:00 https://biolegacyresearch.com/wp-content/uploads/2025/12/BioLegacy-Research-favicon.png